MPA
AGN

Marvin & Palmer Associates’s Allergan Inc AGN Stock Holding History

Marvin & Palmer Associates’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,918
Closed -$734K – 87
2014
Q1 		$734K Buy
+5,918
New +$721K 0.64% 51

Other funds holding AGN

PSCM
Pershing Square Capital Management New York $13.7B AUM 13.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Marvin & Palmer Associates's AGN Position: Q2 2014 in Review

Marvin & Palmer Associates sold out of Allergan Inc (AGN) in Q2 2014, closing a stake of 5,918 shares — an estimated $734K sold.

Marvin & Palmer Associates first reported a position in AGN in Q1 2014 and held it in 1 quarter. The position peaked at $734K in Q1 2014. 770 funds tracked by Wall St. Rank hold AGN as of Q2 2014.

  • Marvin & Palmer Associates reported no remaining Allergan Inc position as of Q2 2014 after selling out during the quarter.
  • Marvin & Palmer Associates sold 5,918 Allergan Inc shares in Q2 2014, an estimated $734K.
  • Marvin & Palmer Associates first reported a position in Allergan Inc in Q1 2014 and held it in 1 quarter.
  • Marvin & Palmer Associates's Allergan Inc position peaked at $734K in Q1 2014.
  • 770 funds tracked by Wall St. Rank held Allergan Inc as of Q2 2014.

Based on Marvin & Palmer Associates's 13F filing for Q2 2014, filed 8 Aug 2014.